Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 16/20 | 0.61 |
| ▸ | KIT | P10721 | 3/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.43 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14597004 | 1.00 | FLT3 (0.61) | FLT3KITPDGFRBMAP4K4SMARCA2 | |
| SCHEMBL13956859 | 0.89 | FLT3 (0.60) | FLT3KITPDGFRBMAP4K4 | |
| SCHEMBL14597011 | 0.89 | FLT3 (0.60) | FLT3KITPDGFRBMAP4K4 | |
| SCHEMBL3883740 | 0.89 | FLT3 (0.60) | FLT3KITPDGFRBMAP4K4 | |
| SCHEMBL3882261 | 0.85 | MAP4K4 (0.55) | FLT3KITPDGFRBMAP4K4SMARCA2 | |
| SCHEMBL3888708 | 0.85 | FLT3 (0.67) | FLT3KITPDGFRB | |
| SCHEMBL3888711 | 0.85 | FLT3 (0.67) | FLT3KITPDGFRB | |
| SCHEMBL28077892 | 0.83 | FLT3 (0.56) | FLT3KITPDGFRB | |
| SCHEMBL3885643 | 0.82 | FLT3 (0.66) | FLT3KITPDGFRB | |
| SCHEMBL3885642 | 0.82 | FLT3 (0.66) | FLT3KITPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898917-B1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-14 | — | — | EP | disclosed |
| EP-1901745-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1898917-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| US-20070021435-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| WO-2006135719-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135713-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281755-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | BAUMANN CHRISTIAN A | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021435-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | FLT3, KIT, TK1 | FLT3 1/4885KIT 2/4885PDGFRB 22/4885 |
| US-20060281755-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | FLT3, CSF3R, CSF1R | FLT3 1/4885KIT 80/4885PDGFRB 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.